$INFI News

Last published 3y ago

3y agoINFIINFINITY DEADLINE REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their OptionsPR NewswireNEW YORK, Sept. 28, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Infinity Pharmaceuticals, Inc. ("Infinity" or the
3y agoINFIINFINITY INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their OptionsPR NewswireNEW YORK, Sept. 23, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Infinity Pharmaceuticals, Inc. ("Infinity" or the
3y agoINFISecurities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their OptionsPR NewswireNEW YORK, Sept. 2, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Infinity Pharmaceuticals, Inc. ("Infinity" or the
3y agoINFIInfinity Pharmaceuticals Announces Value Preservation and Maximization PlanBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming
3y agoINFIInfinity Pharmaceuticals Announces Termination of Merger Agreement with MEI PharmaBusiness WireEganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage
3y agoINFI MEIPMEI Pharma Reminds Shareholders to Vote Today FOR the Infinity TransactionBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special
3y agoINFI MEIPMEI Pharma Encourages Shareholders to Vote FOR the Infinity TransactionBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in
3y agoINFIInfinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI PharmaBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that,
3y agoINFI MEIPMEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity PharmaceuticalsBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the upcoming
3y agoINFI MEIPMEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity PharmaceuticalsBusiness WireGlass Lewis Joins ISS in Recommending that MEI Shareholders Vote FOR the Infinity Transaction MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the Company's pending transaction
3y agoINFI MEIPISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.Business WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate,
3y agoINFI MEIPMEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote "FOR" Pending Transaction with Infinity PharmaceuticalsBusiness WireAffirms Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage
3y agoINFI MEIPMEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity PharmaceuticalsBusiness WireHighlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs Combined Company Well-Positioned to Make a Difference in Cancer Care
3y agoINFI MEIPMEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology CandidatesBusiness WireEvent Available at 8:00 a.m. Eastern Time on June 19, 2023 MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals,
3y agoINFIInfinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer ResearchBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming
3y agoINFIInfinity Pharmaceuticals Reports Full Year 2022 Financial ResultsBusiness Wire– Infinity ended 2022 with total cash and cash equivalents of $38.3 million – – Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates
3y agoHRZN INDT INFI TAMoore Kuehn Encourages HRZN, INDT, INFI, and TA Investors to Contact Law FirmPR NewswireNEW YORK, Feb. 24, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoINFI MEIPMEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology CandidatesBusiness WireCombination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M
3y agoINFI ACUInfinity Inc. vs Acme Inc et al. - AIA Trial, Institution DeniedUS Patent Trial and Appeal Board
3y agoINFIInfinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare ConferenceBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic,
3y agoINFIInfinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire– MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with
3y agoINFIInfinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of EganelisibBusiness Wire–Encouraging one-year progression free survival rates in MARIO-3 1L TNBC study regardless of PD-L1 status– - 52% increase in one-year progression free survival rate in ITT patient population compared to IMpassion130
4y agoINFIInfinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and WebcastBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on
4y agoINFIInfinity to Participate in Wells Fargo and H.C. Wainwright Investor ConferencesBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will
4y agoINFIInfinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire– Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer (UC) patients from MARIO-275 – – MARIO-3 triple negative breast cancer (TNBC) data update on track by year end – – Furth
4y agoINFIInfinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and WebcastBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9th, 2022, at 4:30 p
4y agoINFIInfinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment ConferenceBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate over
4y agoINFIInfinity Pharmaceuticals Reports First Quarter 2022 Financial ResultsBusiness Wire– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer (TNBC) expected to initiate by year-end 2022 – – MARIO-P, a clinical program designed to expand eganelisib development in additi
4y agoINFIInfinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and WebcastBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm E
4y agoINFIInfinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, granted non-statutory stock options to two new employee
4y agoINFIInfinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company HighlightsBusiness Wire– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand eganelisib development in additional solid tumor
4y agoINFIInfinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and WebcastBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, March 29th, 2022 at 4:30 p.
4y agoINFIInfinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare ConferenceBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate over
4y agoINFIInfinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley's 2022 Virtual Oncology ConferenceBusiness WireVirtual fireside chat scheduled for Jan 27th at 10:30 am ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, toda
4y agoINFIInfinity to Present at 40th Annual J.P. Morgan Healthcare ConferenceBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that Adelene Perkins, Chief Executive O
4y agoINFIInfinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 GuidanceBusiness Wire- MARIO-4 registration study in frontline metastatic triple negative breast cancer to be initiated by year end 2022 - - MARIO-P platform study in multiple solid tumors to be initiated on a rolling basis in 3Q 2022 - Infinity Pharmaceuticals, Inc.
4y agoINFI NBIInfinity Pharmaceuticals Added to the NASDAQ Biotechnology IndexBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced it has been selected for addition to the
4y agoINFIInfinity Pharmaceuticals to be Featured in B. Riley Fireside ChatBusiness WireInfinity is being highlighted as part of B. Riley's Fall 2021 Growth Biotech "Best Ideas" research series including an interactive discussion with KOL, Hatem Soliman, MD Virtual fireside chat scheduled for Tuesday, December 14th @ 2:30pm ET Infini
4y agoINFI ISIG LUV RLX+1Thinking about buying stock in Insignia Systems, RLX Technology, Solid Biosciences, Southwest Airlines, or Infinity Pharmaceuticals?PR NewswireNEW YORK, Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISIG, RLX, SLDB, LUV, and INFI. T
4y agoCOMS CXM INFI SLGC+1Thinking about buying stock in Sprinklr, Infinity Pharmaceuticals, COMSovereign, Somalogic, or Viking Therapeutics?PR NewswireNEW YORK, Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CXM, INFI, COMS, SLGC, and VKTX.
4y agoINFIEncouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer SymposiumBusiness Wire-88.6% of Evaluable 1L TNBC Patients Achieved Tumor Reduction- -Disease Control Rate of 92.8% and 81.4% of Evaluable Patients with PD-L1 Positive and PD-L1 Negative Tumors, Respectively- -Median PFS Improvement of 47% and 30% Compared to IMpassion
4y agoINFIInfinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer SymposiumBusiness WireMARIO-3 Phase 2 study evaluating eganelisib added to standard of care Tecentriq® and Abraxane® regimen in frontline triple negative breast cancer (TNBC) Investor Event with KOL Scheduled for Friday, December 10th @ 9:30am ET Infinity Pharmaceu
4y agoINFIInfinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immu
5y agoINFIInfinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company UpdateBusiness Wire– Encouraging data for eganelisib in both PD-L1(-) and PD-L1(+) mTNBC patients, with meaningful prolongation of PFS over IMpassion130 reference benchmark – – Updated mTNBC data to be presented at San Antonio Breast Cancer Symposium – – E
5y agoINFIInfinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and WebcastBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of imm
5y agoARGO CDTX FCEL INFI+1Thinking about buying stock in Realogy Holdings, Cidara Therapeutics, FuelCell Energy, Infinity Pharmaceuticals, or Argo Group?PR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RLGY, CDTX, FCEL, INFI, and ARGO.
5y agoINFIInfinity to Participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies SummitBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immu
5y agoINFIInfinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D., to Its Board of DirectorsBusiness Wire– Experienced leader in immuno-oncology drug development Robert Ilaria, Jr. to head eganelisib clinical development – – Brian Schwartz, M.D., transitioning from Consulting Chief Physician to Infinity's Board of Directors – Infinity Pharma
5y agoINFIInfinity to Participate in Wells Fargo and H.C. Wainwright Investor ConferencesBusiness WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immu
5y agoINFIInfinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4)Business WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced